Company intelligence / Profile preview

Mymee

New York, New York, United Statesmymee.com ↗

Ownership: Private
Development stage: Other

Overview

Peer-reviewed studies show statistically significant improvements in all ten PROMIS® Health Related Quality of Life domains for autoimmune and long COVID patients with moderate to severe symptoms. Mean reduction of >40% in patient-reported symptoms across a wide range of conditions. Over 70% reversed HRQoL severity from moderate-to-severe to mild-to-normal. Results typically seen within eight to seventeen weeks.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Non-pharmacological therapy (digital health intervention)Device (mobile app and data platform)Coaching/behavioral intervention
Industry: Digital Health Medical Devices

Partnerships

Mount Sinai Hospital Post-COVID Recovery ClinicIndustry recognition from Johnson & Johnson innovation leaders and Oscar Health population health leadership

Beyond the preview

Go deeper on Mymee.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mymee.

Explore the full profile